MannKind Corporation (MNKD) on Monday announced that the FDA has accepted their supplemental NDA for the FUROSCIX ReadyFlow Autoinjector.
This device is meant to administer subcutaneous furosemide in less than 10 seconds. The application is set to be reviewed by July 26, 2026.
The ReadyFlow Autoinjector aims to provide adults with chronic heart failure or chronic kidney disease a quicker, at-home method to manage fluid buildup, reducing the time needed from five hours, as with the current On-body Infusor, to mere seconds.
This filing is supported by positive study findings, which demonstrate strong bioavailability and comparable clinical effects to IV furosemide.
MNKD is currently trading at $5.38 up $0.03 or 0.56 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.